Secondary Logo

Journal Logo

Institutional members access full text with Ovid®

Effect of ischemic preconditioning on cardiovascular outcomes in patients with symptomatic coronary artery disease

a cohort study

Rahmi, Rosa M.; Hueb, Whady; Rezende, Paulo C.; Garzillo, Cibele L.; Uchida, Augusto H.; Scudeler, Thiago L.; Ramires, José A.F.; Filho, Roberto K.

doi: 10.1097/MCA.0000000000000748
Original research: PDF Only
Buy
PAP

Background Despite the powerful myocardial protection of ischemic preconditioning (IP) observed in experimental studies, it remains a challenge to observe such protection in humans. Thus, the aim of this study was to evaluate the possible effects of IP on clinical outcomes in patients with coronary artery disease (CAD).

Patients and methods In this cohort study, patients with multivessel CAD, preserved systolic ventricular function, and stable angina were prospectively selected. They underwent two sequential exercise stress tests (EST) to evaluate IP presence. IP was considered present if patients had an improvement in the time to the onset of 1.0-mm ST-segment deviation in the second EST. The primary end point was the composite rate of cardiac death, nonfatal myocardial infarction, or revascularization during 1-year follow-up. Patients with (IP+) and without (IP−) the cardioprotective mechanism were compared regarding clinical end points.

Results A total of 229 patients completed EST and had IP evaluated: 165 (72%) were IP+ and 64 (28%) were IP− patients. Of these, 218 patients had complete follow-up. At 1-year, event-free survival regarding the primary end point was 95.5 versus 83.6% (P=0.0024) and event-free survival regarding cardiac death or myocardial infarction was 99.4 versus 91.7% (P=0.0020), respectively, in IP+ and IP− groups. The unadjusted hazard ratio (IP+/IP−) for the primary end point was 4.63 (1.52–14.08). After multivariate analysis, IP was still significantly associated with better clinical outcomes (P=0.0025).

Conclusion This data suggest that IP may contribute to better clinical outcomes in patients with ischemic heart disease.

Instituto do Coracao (InCor), Hospital das Clinicas HCFMUSP, Faculdade de Medicina, Universidade de Sao Paulo, São Paulo, Brazil

Correspondence to Whady Hueb, MD, PhD, Av. Dr. Eneas de Carvalho Aguiar 44, AB, Sala 114, Cerqueira César, São Paulo 05403-000, Brazil Tel: +55 112 661 5032; fax: +55 112 661 5188; e-mail: mass@incor.usp.br

Received January 11, 2019

Received in revised form January 23, 2019

Accepted March 24, 2019

Copyright © 2019 Wolters Kluwer Health, Inc. All rights reserved.